Novo Nordisk A/S (NVO)
| Market Cap | 306.99B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.40 |
| PE Ratio | 20.52 |
| Forward PE | 16.27 |
| Dividend | $1.18 (1.69%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 6,851,620 |
| Open | 68.41 |
| Previous Close | 69.02 |
| Day's Range | 68.12 - 70.42 |
| 52-Week Range | 57.00 - 145.99 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 112.00 (+60.41%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $112.0, which is an increase of 60.41% from the latest price.
News
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding ...
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Novo Nordisk ties up with WeightWatchers to sell Wegovy
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on ...
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
The Best European Stocks to Buy
European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' ...
Novo Nordisk launches blockuster weight-loss drug Wegovy in India
Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week injection in India.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an up...
Novo Nordisk Ends Partnership with Hims & Hers
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Novo Nordisk under pressure, ends deal with Hims & Hers
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company.
Hims & Hers Health Inc.'s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth-consultatio...
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S‘ NVO phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obe...
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nordisk...
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy ® that put patient safety at risk Novo Nordisk won't stop ta...
Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale
Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.
Novo Nordisk's New Obesity Drug Beats Wegovy Weight Loss in Early Trial
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.